ロード中...

Belimumab for systemic lupus erythematosus

BACKGROUND: Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. OBJECTIVES: To assess the benefits and harms of belimumab (alone or in combination) in system...

詳細記述

保存先:
書誌詳細
出版年:Cochrane Database Syst Rev
主要な著者: Singh, Jasvinder A, Shah, Nipam P, Mudano, Amy S
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Ltd 2021
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095005/
https://ncbi.nlm.nih.gov/pubmed/33631841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010668.pub2
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!